Pfizer (NY:PFE)

27.53 -0.27 (-0.97%)

Delayed Quote Updated: 3:18 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

99 100 Next >

Do Wall Street Analysts Like Bristol-Myers Squibb Stock?

April 29, 2026

Although Bristol-Myers Squibb has lagged behind the SPX over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Via Barchart.com

Topics ETFs

Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

April 29, 2026

From Pfizer Inc.

Via Business Wire

2 High-Yielding Dividend Stocks to Buy for Passive Income in April ↗

April 28, 2026

It's still time to pick up their shares on the dip.

Via The Motley Fool

Topics Economy Intellectual Property

Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗

April 28, 2026

Via Chartmill

Should You Buy, Sell, or Hold Pfizer at $27? ↗

April 28, 2026

The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question mark.

Via The Motley Fool

Topics Intellectual Property

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

April 28, 2026

From Pfizer Inc.

Via Business Wire

Are Wall Street Analysts Bullish on Pfizer Stock?

April 28, 2026

Pfizer has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Via Barchart.com

Topics ETFs Intellectual Property

Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal ↗

April 27, 2026

Today, April 27, 2026, a jumbo all-cash buyout and merger-arb dynamics put Organon in focus.

Via The Motley Fool

Topics Stocks

Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗

April 27, 2026

This pharma stock is cheap for a reason.

Via The Motley Fool

Topics Intellectual Property

VCIT vs. IEI Comes Down to What Job Your Bond Sleeve Is Doing ↗

April 25, 2026

Explore how differences in bond type, risk, and income potential set these two popular ETFs apart for investors.

Via The Motley Fool

Topics Bonds ETFs

Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗

April 25, 2026

The weight loss drug market may reach almost $100 billion in a few years.

Via The Motley Fool

Is Pfizer's 6% Dividend Yield Safe? Here's What Investors Need to Know. ↗

April 25, 2026

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Via The Motley Fool

Topics Earnings

These S&P500 stocks are the most active in today's session ↗

April 24, 2026

Via Chartmill

Unusual Put Activity Is Flagging a Smart Trade Setup in This New Quantum Computing Stock

April 24, 2026

Quantum computing firm Infleqtion led Thursday with a 133.59 Vol/OI ratio. The Jan. 15/2027 $10 put made up 23% of volume, which was 2.8 times its 30-day average, making the trade sneaky smart. Here’s...

Via Barchart.com

Topics Artificial Intelligence Initial Public Offering

Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story.

April 24, 2026

A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside.

Via Barchart.com

Pfizer Declares Second-Quarter 2026 Dividend

April 22, 2026

From Pfizer Inc.

Via Business Wire

Should You Forget Pfizer and Buy This Pharma Stock Instead? ↗

April 22, 2026

Pfizer's shares have rebounded, but is AbbVie still a better buy among pharmaceutical stocks?

Via The Motley Fool

Topics Intellectual Property

Why Merck (MRK) Shares Are Trading Lower Today

April 21, 2026

What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a...

Via StockStory

Topics Government Intellectual Property

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

April 21, 2026

From Pfizer Inc.

Via Business Wire

A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗

April 21, 2026

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Via The Motley Fool

This Drug Stock Has Crushed the S&P 500 Over the Last Decade ↗

April 18, 2026

Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.

Via The Motley Fool

Topics Intellectual Property Stocks

Where Will Pfizer Stock Be in 3 Years? ↗

April 18, 2026

The healthcare giant has been investing heavily in its future growth.

Via The Motley Fool

Topics Intellectual Property

Better Long-Term Buy: Eli Lilly or Viking Therapeutics? ↗

April 17, 2026

One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space.

Via The Motley Fool

Topics Artificial Intelligence

2 Value Stocks to Research Further and 1 Facing Headwinds

April 17, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Via StockStory

QSM Asset Management Loads Up 611,000 Mobileye Shares ↗

April 16, 2026

Mobileye develops advanced driver assistance and autonomous driving technologies for global automotive manufacturers and suppliers.

Via The Motley Fool

Topics Economy Regulatory Compliance Supply Chain

A Fund Just Bet $5.7 Million on Robert Half -- Is the Staffing Sector Due for a Rebound? ↗

April 15, 2026

Robert Half Inc. provides staffing and risk consulting solutions globally to employers across diverse industries.

Via The Motley Fool

Topics Regulatory Compliance

What to Look for Before Buying a Pharma Stock ↗

April 15, 2026

Start with the drug pipeline when researching pharma stocks to own.

Via The Motley Fool

Topics Intellectual Property

QSM Asset Management Bets on Beaten-Down Manpower Group With New $5.9 Million Stake in ManpowerGroup ↗

April 15, 2026

ManpowerGroup provides staffing and HR solutions worldwide, serving clients in 75 countries.

Via The Motley Fool

Topics Regulatory Compliance

J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher

April 15, 2026

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared...

Via MarketMinute

Topics Economy Intellectual Property

MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat

April 14, 2026

In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of...

Via MarketMinute

Topics Bankruptcy Earnings Economy

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.